Discovery of pyrrolo[2,3-d]pyrimidine derivatives with inhibitory effect on liver cancer stem cell
Medicinal Chemistry Research · 2026
DOI: 10.1007/s00044-026-03586-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicinal Chemistry Research, 2026. Verfasst von Xuecong Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medicinal Chemistry for Natural Resource of Ministry of Education, Yunnan Characteristic Plant Extraction Laboratory Co., Ltd., Yun…. Hauptthemen laut MEDLINE: Pyrimidines, Neoplastic Stem Cells, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Applied Basic Research Foundation of Yunnan Province, Project of Yunnan Characteristic Plant Screening and R&D Service CXO Platform.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. The malignancy of HCC is closely linked to liver cancer stem cells (CSCs), making the application of anti-CSC drugs a promising therapeutic approach. In this study, we report the discovery of novel pyrrolo[2,3-d]pyrimidine derivatives as potent inhibitors of liver CSC. Structural optimization and anti-CSC screening led to the identification of improved compounds 6i , 6j , and 7e , which significantly inhibited Huh7 sphere formation while exhibiting low toxicity to standard 2D-cultured tumor cells. Notably, compound 6i sensitizes both parental and Lenvatinib-resistant HCC cells to Lenvatinib treatment, showing a synergistic interaction. Collectively, these findings establish the pyrrolo[2,3-d]pyrimidine as a promising scaffold for targeting liver CSC and provide a potential combination strategy to overcome Lenvatinib resistance in advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medicinal Chemistry for Natural Resource of Ministry of Education, Yunnan Characteristic Plant Extraction Laboratory Co., Ltd., Yunnan Research & Development Center for Natural Products, School of Phar…
- Translational Cancer Research Center, Peking University First Hospital, Beijing, China.
- College of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- International Cancer Institute, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
- Translational Cancer Research Center, Peking University First Hospital, Beijing, China. liurong@bjmu.edu.cn.
- Southwest United Graduate School, 650092, Kunming, China. liurong@bjmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Applied Basic Research Foundation of Yunnan Province
- Project of Yunnan Characteristic Plant Screening and R&D Service CXO Platform
Zitieren
APA
Zhang, X., Chen, X., Wang, L., Chang, Y., Li, J., Yang, J., Ni, D., Zhang, R., Liu, R., & Xiao, W. (2026). Discovery of pyrrolo[2,3-d]pyrimidine derivatives with inhibitory effect on liver cancer stem cell. Medicinal Chemistry Research. https://doi.org/10.1007/s00044-026-03586-7
Vancouver
Zhang X, Chen X, Wang L, Chang Y, Li J, Yang J, et al. Discovery of pyrrolo[2,3-d]pyrimidine derivatives with inhibitory effect on liver cancer stem cell. Medicinal Chemistry Research. 2026. doi:10.1007/s00044-026-03586-7
BibTeX
@article{Zhang2026,
author = {Zhang, Xuecong and Chen, Xuechun and Wang, Liwei and Chang, Yiyuan and Li, Jiaxin and Yang, Jijian and Ni, Dongxuan and Zhang, Ruihan and Liu, Rong and Xiao, Weilie},
title = {Discovery of pyrrolo[2,3-d]pyrimidine derivatives with inhibitory effect on liver cancer stem cell},
journal = {Medicinal Chemistry Research},
year = {2026},
doi = {10.1007/s00044-026-03586-7}
}
EUVIMED